Immediate Fracture Risk After Antihypertensive Drug Initiation

Launched by AJOU UNIVERSITY SCHOOL OF MEDICINE · May 1, 2025

Keywords

ClinConnect Summary

This clinical trial is investigating the risk of fractures that may occur shortly after starting treatment with blood pressure medication. The researchers want to understand if beginning these medications can lead to an increased chance of fractures in adults who are 50 years or older. They will look at data from health records to compare fracture rates in patients who just started blood pressure medication to those who have not started yet. They are also interested in comparing the safety of two different types of blood pressure treatments: a single medication versus a combination of two medications.

To participate in this study, individuals must be at least 50 years old, have been diagnosed with high blood pressure, and have not used any blood pressure medications in the year before starting the study. Participants should also have a clean health record, meaning they should not have had recent hospital stays, serious injuries, or certain medical conditions that could affect the results. If you join this study, you will help researchers better understand the immediate effects of blood pressure medications on fracture risk, which could lead to safer treatment options in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Individuals with at least 365 days of continuous observation prior to the index date (defined as the date of first antihypertensive medication prescription), with no prior antihypertensive use during that period
• • At least one diagnosis of hypertension (ICD-10 codes I10-I13, I15) recorded within 180 days before the index date
• Exclusion Criteria (main cohort):
• • Any of the following occurring in the 365 days prior to the index date: Hospitalization (inpatient admission, including long-term care facility), transport-related trauma (ICD-10 codes V01-V99), Intentional self-harm (ICD-10 codes X60-X84, Y87), History of pathological fractures (e.g., M84.4, M90.7), Evidence of end-stage renal disease (ESRD), dialysis, kidney transplant, renal osteodystrophy